HRMY
Harmony Biosciences Holdings
NASDAQ: HRMY · HEALTHCARE · BIOTECHNOLOGY
$31.05
-0.35% today
Updated 2026-04-29
Market cap
$1.80B
P/E ratio
11.46
P/S ratio
2.07x
EPS (TTM)
$2.71
Dividend yield
—
52W range
$26 – $41
Volume
1.1M
WallStSmart proprietary scores
57
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B9.0
Quality
A+8.0
Profitability
A8.3
Valuation
A4/9
Piotroski F-Score
Moderate
3.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$43.00
+38.49%
12-Month target
$22.07
-28.92%
Intrinsic (DCF)
$64.38
Margin of safety
+43.17%
2 Strong Buy4 Buy4 Hold0 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.28 — safe zone
+ ROE 20.70% — strong efficiency
+ Free cash flow $126.04M — positive
+ Revenue growth 21.10% QoQ
+ 43.17% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $437.86M | $582.02M | $714.73M | $868.45M | $868.45M |
| Net income | $181.47M | $128.85M | $145.49M | $158.69M | $22.49M |
| EPS | — | — | — | — | $2.71 |
| Free cash flow | $144.29M | $219.07M | $218.67M | $347.89M | $126.04M |
| Profit margin | 41.44% | 22.14% | 20.36% | 18.27% | 18.30% |
Peer comparison
Smart narrative
Harmony Biosciences Holdings trades at $31.05. representing a P/E of 11.46x trailing earnings. Our Smart Value Score of 57/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 3.28, it sits in the safe zone. TTM revenue stands at $868.45M. with profit margins at 18.30%. Our DCF model estimates intrinsic value at $64.38.
Frequently asked questions
What is Harmony Biosciences Holdings's stock price?
Harmony Biosciences Holdings (HRMY) trades at $31.05.
Is Harmony Biosciences Holdings overvalued?
Smart Value Score 57/100 (Grade C+, Hold). DCF value $64.38.
What is the price target of Harmony Biosciences Holdings (HRMY)?
The analyst target price is $43.00, representing +38.5% upside from the current price of $31.05.
What is the intrinsic value of Harmony Biosciences Holdings (HRMY)?
Based on our DCF model, intrinsic value is $64.38, a +43.2% margin of safety versus $31.05.
What is Harmony Biosciences Holdings's revenue?
TTM revenue is $868.45M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
3.28 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.07x
ROE20.70%
Beta0.89
50D MA$28.98
200D MA$33.02
Shares out0.06B
Float0.05B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—